Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive DisorderA Randomized, Double-Blind, Placebo-Controlled Trial

被引：0
作者：
Neda Askari
Mahdieh Moin
Mohammad Sanati
Masih Tajdini
Seyed-Mohammad-Reza Hosseini
Amirhossein Modabbernia
Babak Najand
Samrand Salimi
Mina Tabrizi
Mandana Ashrafi
Reza Hajiaghaee
Shahin Akhondzadeh
机构：
[1] Tehran University of Medical Sciences,Psychiatric Research Center, Roozbeh Hospital
[2] Tehran University of Medical Sciences,Baharloo Hospital
[3] Tehran University of Medical Sciences,Department of Medical Genetics, Faculty of Medicine
[4] Institute of Medicinal Plants (ACECR),undefined
来源：
CNS Drugs | 2012年 / 26卷
关键词：
Ondansetron; Fluvoxamine; Granisetron; Quinpirole; Tropisetron;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Several small studies have shown beneficial effects of ondansetron, a serotonin 5-HT3 receptor antagonist, in the treatment of obsessivecompulsive disorder (OCD). The efficacy of other 5-HT3 receptor antagonists in patients with OCD is still unclear. Granisetron does not alter cytochrome P450 activity and might have a lower risk of drug interactions, a longer duration of action and a better tolerability profile than other 5-HT3 receptor antagonists.
引用
收藏
页码：883 / 892
页数：9
相关论文
共 141 条
[21]  
Broocks A.(2005)Prolonged increase in the sensitivity of the posterior ventral tegmental area to the reinforcing effects of ethanol following repeated exposure to cycles of ethanol access and deprivation J Pharmacol Exp Ther 315 648-57
[22]  
Pigott T.A.(2010)A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder Hum Psychopharmacol 25 509-13
[23]  
Hill J.L.(2005)Updated overview of the putative role of the serotoninergic system in obsessivecompulsive disorder Neuropsychiatr Dis Treat 1 231-43
[24]  
Eapen V.(1994)Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron Br J Clin Pharmacol 38 557-66
[25]  
Robertson M.M.(2003)Granisetron: relating pharmacology to clinical efficacy Support Care Cancer 11 93-100
[26]  
Alsobrook J.P.(1989)The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability Arch Gen Psychiatry 46 1006-11
[27]  
Tibbo P.(1989)The Yale-Brown Obsessive Compulsive Scale: II. Validity Arch Gen Psychiatry 46 1012-6
[28]  
Kroetsch M.(2006)Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines Prog Neuropsychopharmacol Biol Psychiatry 30 400-12
[29]  
Chue P.(1994)Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison J Clin Psychiatry 55 301-5
[30]  
Zhang Z.J.(1996)Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison J Clin Psychopharmacol 16 121-9
12345678910